Daniel L. Hertz

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 31 papers. Top paper: “Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update”.

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update

Journal of Clinical Oncology(2020)10.1200/jco.20.01399

N/A

1.0DataRank · unranked

995 citations

Christina Lacchetti, Jonathan Bleeker, Guido Cavaletti, Cynthia Chauhan, Daniel L. Hertz +11 more

Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7062

N/A

0.883DataRank · unranked

27 citations

Gary Zirpoli, William E. Barlow, G. Thomas Budd, Bryan McKiver, Lajos Pusztai +10 more

Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912)

Supportive Care in Cancer(2021)10.1007/s00520-021-06371-x

N/A

0.603DataRank · unranked

9 citations

Travis Dockter, Daniel Satele, Charles L. Loprinzi, Jennifer Le‐Rademacher, Daniel L. Hertz

Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy

JCO Oncology Practice(2022)10.1200/op.21.00874

N/A

0.520DataRank · unranked

31 citations

Amy L. Pasternak, N. Lynn Henry, Vaibhav Sahai, Daniel L. Hertz, Kyoin Koo

Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221

Research Square(2023)10.21203/rs.3.rs-3242513/v1

N/A

0.104DataRank · unranked

1 citations

Gary Zirpoli, G. Thomas Budd, William E. Barlow, Lajos Pusztai, Gabriel N. Hortobágyi +8 more

Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure: Short report

UNC Libraries(2020)10.17615/f7dc-gg49

N/A

0DataRank · unranked

0 citations

Kristan Rollins, Christine M. Walko, J. M. Herendeen, J. Heyward Hull, Arlene S. Bridges +3 more

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel

UNC Libraries(2020)10.17615/cyk5-ch98

N/A

0DataRank · unranked

0 citations

Stacey J. Winham, Howard L. McLeod, E. Claire Dees, Amy Drobish, Daniel L. Hertz +2 more

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

Frontiers in Genetics(2021)10.3389/fgene.2021.662734

N/A

0DataRank · unranked

14 citations

Karen L. Smith, Yuhua Zong, Christina L. Gersch, Andrea M. Pesch, Jennifer Lehman +6 more

Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines

Pharmacogenetics and Genomics(2020)10.1097/fpc.0000000000000419

N/A

0DataRank · unranked

0 citations

Tammy M. Havener, Daniel L. Hertz, Jeremy R. Ash, Alexandra Larson, Lisa A. Carey +3 more

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel

UNC Libraries(2021)10.17615/q1m1-ke46

N/A

0DataRank · unranked

6 citations

Alison A. Motsinger‐Reif, E. C. Dees, A. Drobish, S. Roy, L. S. Clark +3 more

Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy

UNC Libraries(2021)10.17615/czyq-fx53

N/A

0DataRank · unranked

0 citations

Stefanie D. Krens, Daniel L. Hertz, Howard L. McLeod

Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12090

N/A

0DataRank · unranked

0 citations

Travis Dockter, Daniel Satele, Charles L. Loprinzi, Jennifer Le‐Rademacher, Daniel L. Hertz

Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing

British Journal of Clinical Pharmacology(2022)10.1111/bcp.15244

N/A

0DataRank · unranked

18 citations

Li Chen, N. Lynn Henry, Jennifer J. Griggs, Daniel F. Hayes, Brian A. Derstine +4 more

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms

Research Square(2022)10.21203/rs.3.rs-1315678/v1

N/A

0DataRank · unranked

5 citations

Julie A. Douglas, Robert M. Miller, Kelley M. Kidwell, Christina L. Gersch, Zeruesenay Desta +7 more

Co-occurrence and Metabolic Biomarkers of Sensory and Motor Subtypes of Peripheral Neuropathy from Paclitaxel

Research Square(2022)10.21203/rs.3.rs-1251386/v1

N/A

0DataRank · unranked

1 citations

Elizabeth Smith, Kathleen A. Stringer, N. Lynn Henry, Daniel L. Hertz, Ciao-Sin Chen

Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12024

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Dawn L. Hershman, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan +8 more

Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e13535

N/A

0DataRank · unranked

0 citations

Nicholas B. Larson, Timothy M. Pierpont, Nancy L. Bartlett, Andrew D. Zelenetz, Wyndham H. Wilson +5 more

Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy

Current Opinion in Supportive and Palliative Care(2023)10.1097/spc.0000000000000684

N/A

0DataRank · unranked

17 citations

Daniel L. Hertz

Risk of Toxicity From Topical 5‐Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles

Clinical Pharmacology & Therapeutics(2023)10.1002/cpt.3131

N/A

0DataRank · unranked

3 citations

Amy L. Pasternak, N. Lynn Henry, Vaibhav Sahai, Daniel L. Hertz, J. Quesada Granados

DPYD Testing: Time to Put Patient Safety First

Journal of Clinical Oncology(2023)10.1200/jco.22.02364

N/A

0DataRank · unranked

40 citations

Susan E. Bates, Gabriel A. Brooks, William L. Dahut, Robert B. Diasio, Wafik S. El‐Deiry +17 more

Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12003

N/A

0DataRank · unranked

11 citations

Joseph M. Unger, Dawn L. Hershman, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan +9 more

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations

European Journal of Cancer(2024)10.1016/j.ejca.2024.114024

N/A

0DataRank · unranked

26 citations

Markus Joerger, Yung‐Jue Bang, Ron H.J. Mathijssen, Caicun Zhou, Li Zhang +6 more

Recommendations for pharmacogenetic testing in clinical practice guidelines in the US

American Journal of Health-System Pharmacy(2024)10.1093/ajhp/zxae110

N/A

0DataRank · unranked

23 citations

Chad Bousman, Howard L. McLeod, Andrew A. Monte, Deepak Voora, Lori A. Orlando +6 more

Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04677-1

N/A

0DataRank · unranked

5 citations

Yue Cheng, Daniel L. Hertz, Yuchen Sun

Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation

JAMIA Open(2024)10.1093/jamiaopen/ooae006

N/A

0DataRank · unranked

1 citations

Vered Stearns, Amanda L. Blackford, Daniel L. Hertz, Karen L. Smith, James M. Rae +2 more

Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04680-6

N/A

0DataRank · unranked

1 citations

Gary Zirpoli, G. Thomas Budd, William E. Barlow, Lajos Pusztai, Gabriel N. Hortobágyi +8 more

Plasma proteomics to predict taxane-induced peripheral neuropathy

(2024)10.22541/au.172066987.71730545/v1

N/A

0DataRank · unranked

0 citations

Yaping Liu, N. Lynn Henry, Manjunath P. Pai, Hao‐Jie Zhu, Daniel L. Hertz +1 more

Factors influencing the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy among patients with metastatic breast cancer: a best–worst scaling

Supportive Care in Cancer(2025)10.1007/s00520-025-09508-4

N/A

0DataRank · unranked

1 citations

John F. P. Bridges, Daniel L. Hertz, Maryam B. Lustberg, Hetal Vachhani, Erin Hickey +3 more

Expanding biobank pharmacogenomics through machine learning calls of structural variation

Genetics(2025)10.1093/genetics/iyaf088

N/A

0DataRank · unranked

0 citations

Amy L. Pasternak, Lars G. Fritsche, Emily M. Bertucci, Snehal Patil, Michael Boehnke +5 more

Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity

UNC Libraries(2020)10.17615/97a9-xw23

N/A

0DataRank · unranked

0 citations

Yijing He, Howard L. McLeod, Jane Yen Revollo, Robert Brown, Paul, Jim +4 more

Genetic Variation in Charcot–Marie–Tooth Genes Contributes to Sensitivity to Paclitaxel-Induced Peripheral Neuropathy

Pharmacogenomics(2020)10.2217/pgs-2020-0053

N/A

0DataRank · unranked

14 citations

Fang Fang, Kelley M. Kidwell, Kiran Vangipuram, Lauren A. Marcath, Christina L. Gersch +7 more